Transplantation of neonatal porcine islets and sertoli cells into nonimmunosuppressed nonhuman primates

Isaac, John; Skinner, Sarah; Elliot, R.B.; Salto-Tellez, Manuel; Garkavenko, Olga; Khoo, Ai Leng; Lee, Kok-Onn; Calne, R. Y.; Wang, D.Z.

doi:10.1016/j.transproceed.2004.11.062

Cited by 21 publications

(9 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the extent of their protective effect is unclear, and it is not known which genetic modification might provide further protection. The transplantation of pig NICC in non-human primates (NHP) has led to successful outcomes [3,[28][29][30][31][32].…”

Section: Introductionmentioning

confidence: 99%

In vitro exposure of pig neonatal isletlike cell clusters to human blood

Nagaraju

Bertera

Tanaka

et al. 2015

Xenotransplantation

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

In vitro exposure of pig neonatal isletlike cell clusters to human blood

Nagaraju

Bertera

Tanaka

et al. 2015

Xenotransplantation

View full text Add to dashboard Cite

show abstract

“…Recently, it was reported that co‐transplantation of neonatal porcine Sertoli cells with islets into diabetic rats did not contribute to graft survival compared to transplantation of islets alone (12). Moreover, the beneficial effect of co‐transplantation of porcine Sertoli cells could not be confirmed in a non‐human primate model of porcine islet transplantation; although in this study no subcutaneous stents were used, no long‐term survival was found when neonatal islets, with or without co‐cultured Sertoli cells, were transplanted into various sites of non‐diabetic non‐immunosuppressed macaques (13).…”

Section: Clinical Trials Reported To Datementioning

confidence: 70%

Islet Xenotransplantation: Are We Really Ready for Clinical Trials?

Rood

Cooper

2006

American Journal of Transplantation

View full text Add to dashboard Cite

Four clinical trials of porcine islet transplantation have been reported, and there are verbal reports that clinical trials on much larger scales are continuing in centers in China and Russia. The four reported trials are briefly reviewed and, in the light of the present status of experimental islet xenotransplantation, consideration is given to whether such trials are currently justified. The Ethics Committee of the International Xenotransplantation Association has (1) emphasized the need for encouraging studies in non-human primates before clinical trials should be undertaken, (2) mandatory monitoring for the transfer of porcine microorganisms, and (3) careful regulation and oversight by recognized bodies. Other aspects of the topic, such as the need for informed consent, are briefly discussed. We conclude that, at the present time, more data documenting convincing efficacy, focused on clinically applicable immunosuppressive regimens, are needed to justify the initiation of closely monitored clinical trials. A clinical trial may then be justified even though the potential risk to the patients, and possibly for society, will not be zero.

show abstract

“…Absence of PERV infection was also documented after transgenic porcine liver perfusion in baboons and in 27 pig-tobaboon kidney and heart xenotransplantation procedures with a protocol involving depletion of galactose a(1,3) galactose (a-Gal) antibodies [14,15]. No PERV was detected in the blood of nonimmunosuppressed nonhuman primates transplanted with porcine islet cells as long as 8 weeks after transplantation [16,17]. PERV transmission was not demonstrated in patients experimentally treated with bioartificial porcine livers for acute liver failure [18,19].…”

Section: Transmissionmentioning

confidence: 97%